Go Deep
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,692 | -2.4 | 1.96 | 0.00 | 474.26 |
| Oct 2026 | 20,032 | -2.2 | 1.82 | 0.00 | 439.61 |
| Oct 2026 | 20,129 | -2.3 | 1.78 | 0.00 | 430.17 |
| Oct 2026 | 20,333 | -2.1 | 1.70 | 0.00 | 409.17 |
| Oct 2026 | 20,265 | -2.1 | 1.73 | 0.00 | 416.24 |
| Oct 2026 | 20,192 | -2.1 | 1.75 | 0.00 | 423.36 |
| Oct 2026 | 20,567 | -1.9 | 1.60 | 0.00 | 385.90 |
| Oct 2026 | 20,596 | -1.9 | 1.59 | 0.00 | 382.28 |
Atea Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -32,933,000.0 | -45,440,000.0 | -44,867,000.0 | -42,049,000.0 |
| EPS | -0.4 | -0.6 | -0.6 | -0.5 |
Atea Pharmaceuticals, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -158,349,000.0 | -168,385,000.0 | -135,956,000.0 | -115,909,000.0 |
| EPS | -1.9 | -2.0 | -1.6 | -1.4 |
Atea Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 315,218,000.0 | 464,668,000.0 | 594,968,000.0 | 666,708,000.0 | — |
| Total Liabilities | 39,784,000.0 | 25,801,000.0 | 39,776,000.0 | 26,136,000.0 | — |
| Total Equity | 275,434,000.0 | 438,867,000.0 | 555,192,000.0 | 640,572,000.0 | — |
Owes vs Owns
Atea Pharmaceuticals, Inc. owed $0.12 for every $1 it owned in Jun 2026, up from $0.04 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.12× | 0.13× | 0.06× | 0.07× | 0.04× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Atea Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 95.8%Other assets 3.9%
How it's funded — Dec 2025
Payables 4.1%Other liabilities 8.2%Shareholders' equity 87.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 301.8 | 454.7 | 578.1 | 646.7 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.1 | 2.1 | 3.1 | 4.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 12.3 | 7.8 | 13.7 | 15.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.8 | 0.8 | 0.8 | 0.7 |
| Long-term debt | 0.0 | 0.8 | 1.6 | 2.4 |
| Payables | 12.9 | 4.5 | 4.3 | 2.6 |
| Other liabilities | 26.0 | 19.7 | 33.1 | 20.5 |
| Shareholders' equity | 275.4 | 438.9 | 555.2 | 640.6 |
| Net tangible assets | 275.4 | 438.9 | 555.2 | 640.6 |
Atea Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -132,031,000.0 | -135,499,000.0 | -85,395,000.0 | -120,982,000.0 | — |
| Investing Activities | 188,793,000.0 | 56,105,000.0 | 40,303,000.0 | -455,410,000.0 | — |
| Financing Activities | -25,745,000.0 | 267,000.0 | 257,000.0 | 370,000.0 | — |